Rosuvastatin
 |
|
| Clinical data | |
|---|---|
| Pronunciation | roh-SOO-və-sta-tin |
| Trade names | Crestor |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a603033 |
| Pregnancy category |
|
| Routes of administration |
By mouth (tablets) |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 20% |
| Protein binding | 88% |
| Metabolism | Liver: CYP2C9 (major) and CYP2C19-mediated; ~10% metabolized |
| Metabolites | N-desmethyl rosuvastatin (major; 1/6–1/9 of rosuvastatin activity) |
| Biological half-life | 19 hours |
| Excretion | Faeces (90%) |
| Identifiers | |
|
|
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| ECHA InfoCard | 100.216.011 |
| Chemical and physical data | |
| Formula | C22H28FN3O6S |
| Molar mass | 481.539 |
| 3D model (Jmol) | |
|
|
|
|
  (what is this?)
|
|
Rosuvastatin (INN), marketed as Crestor, is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to treat high cholesterol and related conditions, and to prevent cardiovascular disease.
It was developed by Shionogi. In 2013 Crestor was the fourth-highest selling drug in the United States, accounting for approx. $5.2 billion in sales. A generic version became available in the United States in 2016.
The primary use of rosuvastatin is for the treatment of dyslipidemia.
The effects of rosuvastatin on LDL cholesterol are dose-related. Higher doses were more efficacious in improving the lipid profile of patients with hypercholesterolemia than milligram-equivalent doses of atorvastatin and milligram-equivalent or higher doses of simvastatin and pravastatin.
Meta-analysis showed that rosuvastatin is able to modestly increase levels of HDL cholesterol as well, as with other statins. A 2014 Cochrane review determined there was good evidence for rosuvastatin lowering non-HDL levels linearly with dose. HDL increases by 7% with no dose effect noted.
Side effects are uncommon. The following side effects should be reported to the prescribing doctor if they persist or get worse:
The following rare side effects are more serious. Like all statins, rosuvastatin can possibly cause myopathy, rhabdomyolysis. Stop taking rosuvastatin and contact the prescribing doctor if any of these occur:
If any signs of an allergic reaction develop, contact an emergency medical service immediately:
Rosuvastatin has multiple contraindications, conditions that warrant withholding treatment with rosuvastatin, including hypersensitivity to rosuvastatin or any component of the formulation, active liver disease, elevation of serum transaminases, pregnancy, or breastfeeding. Rosuvastatin must not be taken while pregnant as it can cause serious harm to the unborn baby. In the case of breastfeeding, it is unknown whether rosuvastatin is passed through breastmilk, but due to the potential of disrupting the infant's lipid metabolism, patients should not breast feed while on rosuvastatin.
...
Wikipedia